| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/07/2012 | US8110571 Tyrosine kinase inhibitors; antiproliferation agents; metabolism diseases; antiallergens; central nervous system disorders; vision and skin disorders; antiarthritic agents |
| 02/07/2012 | US8110570 Modulators of acetyl-coenzyme A carboxylase and methods of use thereof |
| 02/07/2012 | US8110569 Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use |
| 02/07/2012 | US8110568 Inhibitors of IAP |
| 02/07/2012 | US8110567 Phenyl-piperazine derivatives as serotonin reuptake inhibitors |
| 02/07/2012 | US8110566 Therapeutic agents 713 |
| 02/07/2012 | US8110565 Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release |
| 02/07/2012 | US8110564 Bile acid or bile salt fatty acid conjugates |
| 02/07/2012 | US8110563 Fire ant killer (“F.A.K.”)/ insecticide |
| 02/07/2012 | US8110562 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| 02/07/2012 | US8110559 Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| 02/07/2012 | US8110558 Oligomeric compounds and compositions for use in modulation of small non-coding RNAS |
| 02/07/2012 | US8110557 Gamma secretase inhibitor for treatment of herpesvirus infection |
| 02/07/2012 | US8110555 7-hydroxy chromones as potent antioxidants |
| 02/07/2012 | US8110541 Antigen delivery vectors and constructs |
| 02/07/2012 | US8110540 Antigen delivery vectors and constructs |
| 02/07/2012 | US8110399 Isolating nestin-positive stem cells, expanding and translplanting into a patient to replace lost or damaged insulin secreting cells; differentiating pancreatic stem cells to obtain cells that produce insulin and other hormones |
| 02/07/2012 | US8110378 Nucleic acids encoding DCRS5 |
| 02/07/2012 | US8110367 Methods for diagnosing renal disorders |
| 02/07/2012 | US8110229 Herbal composition for reducing ADD/ADHD and method thereof |
| 02/07/2012 | US8110226 Drug formulations having inert sealed cores |
| 02/07/2012 | US8110225 Treatment using dantrolene |
| 02/07/2012 | US8110224 Matrix containing biodegradable polymer, water soluble polymer and drugs; mixture containing water insoluble surfactant such as lecithin or phosphatide |
| 02/07/2012 | US8110205 Silver-containing inorganic antibacterial |
| 02/07/2012 | US8110182 Treatment of multiple sclerosis by administration of interferon alpha and C-phycocyanin |
| 02/07/2012 | US8110179 A water-soluble, cyclodextrin-containing linear polymer having bioactive moieties to attached a drug(s) or modified drug to the polymer covalently; cleavage under biological conditions to release the bioactive moieties; sustained release; side effect reduction; stability; nontoxic; drug polymer conjugate |
| 02/07/2012 | US8110177 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 02/07/2012 | CA2669915C Substituted bicyclocarboxyamide compounds |
| 02/07/2012 | CA2666829C Use of estradiol valerate or 17.beta.-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido |
| 02/07/2012 | CA2663829C Dithiolopyrrolones compounds and their therapeutical applications |
| 02/07/2012 | CA2663366C Compounds and compositions as protein kinase inhibitors |
| 02/07/2012 | CA2655754C 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidine derivatives, methods for their preparation and their use as antiviral agents |
| 02/07/2012 | CA2648569C Pyridyl amide t-type calcium channel antagonists |
| 02/07/2012 | CA2632433C Methods for preparing macrocyclic analogs and intermediates for preparing same |
| 02/07/2012 | CA2597327C Antibiotic macrolides |
| 02/07/2012 | CA2584524C Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
| 02/07/2012 | CA2568823C Vaginally administrable progesterone-containing tablets and method for preparing same |
| 02/07/2012 | CA2522295C Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom |
| 02/07/2012 | CA2520128C Process for the preparation of n-substituted 2-cyanopyrrolidines |
| 02/07/2012 | CA2519351C Controlled release system |
| 02/07/2012 | CA2517370C Manganese based organometallic complexes, pharmaceutical compositions and dietetic products |
| 02/07/2012 | CA2516514C Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| 02/07/2012 | CA2510006C Compositions comprising a combination of diphenyl urea impdh inhibitors and apoptosis-inducing anti-cancer agents |
| 02/07/2012 | CA2505286C Novel ligands that are antagonists of rar receptors, process for preparing them and use thereof in human medicine and in cosmetics |
| 02/07/2012 | CA2497898C Liquid stable composition of oxazaphosphorine with mesna |
| 02/07/2012 | CA2497640C Medical device having hydration inhibitor |
| 02/07/2012 | CA2492404C Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| 02/07/2012 | CA2488535C Glucocorticoid receptor ligands for the treatment of metabolic disorders |
| 02/07/2012 | CA2486144C Compositions comprising an angiotensin receptor blocker, a calcium channel blocker and a diuretic |
| 02/07/2012 | CA2480826C Oral pharmaceutical formulation in the form of microcapsule aqueous suspension allowing modified release of active ingredient(s) |
| 02/07/2012 | CA2479057C Compressed tablets comprising microcapsules with modified release |
| 02/07/2012 | CA2471046C Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine |
| 02/07/2012 | CA2471044C Benzimidazole derivatives and their use as gnrh antagonists |
| 02/07/2012 | CA2466536C Transdermal transport of compounds |
| 02/07/2012 | CA2460655C Combination of selected opioids with muscarine antagonists for treating urinary incontinence |
| 02/07/2012 | CA2434747C Camptothecin derivatives |
| 02/07/2012 | CA2385312C Compositions and methods for preventing and treating transplant rejection |
| 02/07/2012 | CA2366785C Soluble tumor necrosis factor receptor treatment of medical disorders |
| 02/07/2012 | CA2301964C Agonist antibodies to the thrombopoietin receptor, and their therapeutic uses |
| 02/07/2012 | CA2264484C Human plasma hyaluronidase |
| 02/05/2012 | CA2746981A1 Methods for inhibition of apolipoprotein h |
| 02/05/2012 | CA2713777A1 Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream |
| 02/02/2012 | WO2012016217A1 Ampk-activating heterocyclic compounds and methods for using the same |
| 02/02/2012 | WO2012016181A2 Anti-allergy lozenges |
| 02/02/2012 | WO2012016162A2 Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| 02/02/2012 | WO2012016148A1 Treatment of metabolic syndrome and insulin resistance with citrus flavanones |
| 02/02/2012 | WO2012016145A2 Mitochondrial apoptosis-induced inflammation |
| 02/02/2012 | WO2012016133A2 Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| 02/02/2012 | WO2012016111A1 Hydrated sodium salt form of celecoxib |
| 02/02/2012 | WO2012016109A2 Compounds and methods for skin repair |
| 02/02/2012 | WO2012016082A1 Quinoline derivatives and melk inhibitors containing the same |
| 02/02/2012 | WO2012016081A2 Method and therapeutic for the treatment and regulation of memory formation |
| 02/02/2012 | WO2012016050A2 Chemoradiotherapy for kras-mutant colorectal cancer |
| 02/02/2012 | WO2012016048A1 Anti- viral azide-containing compounds |
| 02/02/2012 | WO2012016044A1 Anti-viral azide containing compounds |
| 02/02/2012 | WO2012016001A1 Cyclic amine azaheterocyclic carboxamides |
| 02/02/2012 | WO2012015999A2 Process for the preparation of imatinib mesylate |
| 02/02/2012 | WO2012015986A2 Substituted dioxopiperidinyl phtalimide derivatives |
| 02/02/2012 | WO2012015972A1 Compositions and methods for inhibition of the jak pathway |
| 02/02/2012 | WO2012015950A1 Use of rasagiline for the treatment of olfactory dysfunction |
| 02/02/2012 | WO2012015946A1 Dispersion of rasagiline citrate |
| 02/02/2012 | WO2012015944A2 Novel tetrahydronaphalene antagonists to the thromboxane a2 (tp) receptor |
| 02/02/2012 | WO2012015937A2 Parp1 targeted therapy |
| 02/02/2012 | WO2012015914A2 Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| 02/02/2012 | WO2012015901A1 Methods for treating gastric and pancreatic malignancies |
| 02/02/2012 | WO2012015882A1 Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
| 02/02/2012 | WO2012015875A1 Methods for treating hematological malignancies |
| 02/02/2012 | WO2012015820A1 Composition and method for photodynamic disinfection |
| 02/02/2012 | WO2012015810A2 Pharmaceutical compositions containing pemetrexed having extended storage stability |
| 02/02/2012 | WO2012015789A2 Composition and method for the topicaltreatment of dermatitis |
| 02/02/2012 | WO2012015775A2 Sirna targeting vegfa and methods for treatment in vivo |
| 02/02/2012 | WO2012015758A2 Methods of treating pain |
| 02/02/2012 | WO2012015750A2 Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies |
| 02/02/2012 | WO2012015749A1 Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors |
| 02/02/2012 | WO2012015715A1 Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
| 02/02/2012 | WO2012015704A2 Peripherally restricted faah inhibitors |
| 02/02/2012 | WO2012015693A1 Imidazole derivatives |
| 02/02/2012 | WO2012015677A1 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
| 02/02/2012 | WO2012015599A1 Methods to identify targets and molecules regulating purinosomes and their uses |
| 02/02/2012 | WO2012015487A1 Combination of dapsone with adapalene |